Ignite Creation Date:
2024-05-06 @ 9:24 AM
Last Modification Date:
2024-10-26 @ 12:14 PM
Study NCT ID:
NCT02977299
Status:
COMPLETED
Last Update Posted:
2022-04-27
First Post:
2016-11-28
Brief Title:
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Study Overview
Official Title:
Augmentation Versus Switch Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With Treatment Resistant Depression ASCERTAIN-TRD
Status:
COMPLETED
Status Verified Date:
2022-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ASCERTAINTRD
Brief Summary:
This is a multi-site randomized open-label effectiveness trial comparing three treatment arms for Major Depressive Disorder MDD patients with TRD who are currently on ongoing stable and adequate antidepressant therapy ADT Adequate ADT is defined as a therapeutically sufficient dose for a sufficient treatment period which would be expected to be effective as listed in the MGH Antidepressant Treatment Response Questionnaire ATRQ Patients will be randomized in a 111 fashion to one of three open-label treatment arms a aripiprazole augmentation b rTMS augmentation and c switching to venlafaxine XR or Duloxetine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None